Caribou Biosciences, Inc. (CRBU)
- Sector
- Biotechnology
- Last price
- $0.47
- As of
Kresmion compiles this page from CRBU's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Caribou Biosciences, Inc. (CRBU): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full CRBU dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRBU on one page. Preview it with sample data, then open it live with a free account.
Preview the CRBU dossierActive signals for CRBU
- highCONSENSUS_SELL
4 tracked funds reduced CRBU this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 25.7%, EPS $-0.24 vs $-0.3232 estimate
- highCONSENSUS_SELL
3 tracked funds reduced CRBU this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 50% of CRBU (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +79% to CRBU (2026Q2)
FREE, NO ACCOUNT
Every signal on CRBU, as it fires
You are seeing 5 of 14 signals recorded on CRBU since 2026-05-26.
The five above landed across 3 days. The other 9 were recorded on 2 other days. 7 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRBU (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 142038108 · 2026Q2 | $4.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 142038108 · 2026Q2 | $1.8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 142038108 · 2026Q2 | $90K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 142038108 · 2026Q2 | $71K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 142038108 · 2026Q2 | $28K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRBU
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CRBU against its peers
CRBU's operating margin of -1329.4% ranks in the 65th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | CRBU | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 11.2M USD | 130000 USD | 79 | 11 |
| Operating margin | -1329.4% | -6056.4% | 65 | 9 |
| Net margin | -1327.4% | -5668.6% | 65 | 9 |
| Return on equity | -121.2% | -123.1% | 55 | 20 |
| 1 year | -80.3% | -52.7% | 15 | 22 |
Peers (24): DWTX, TIL, CRVO, ELTX, IMA, ANVS, SER, INMB, IBO, EXOZ, HOWL, GUTS, FLNA, LONA, PDSB, VERU, ALDX, CELU, GRCE, IBIO, ATHE, TVGN, HYPD, GOSS. Left out: BSEM (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CRBU: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRBU on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRBU for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.